can lead to huge difference in annual cost burden to the patient.Conclusions: This significant cost difference between costliest and cheapest brands of insulin glargine vials assumes even further importance since majority of the diabetics need to bear the cost of multiple drugs prescribed to them, on...
For instance, Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). However, the companies are working on various innovations, such as Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for treating type-1 and type-...